Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226421 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
A Phase 3 study of Chronic Pain, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT00226421: Completed Phase 3 study of Chronic Pain, sponsored by Endo Pharmaceuticals.
NCT00226421 is a Phase 3 study of Chronic Pain that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 120 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226421, a Phase 3 study of Chronic Pain, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
Conditions Studied
Interventions
- DRUG Oxymorphone Extended Release
Study Locations (20)
Florida
- Radiant Research - Daytona Beach
- University Clinical Research - DeLand
- LCFP Inc. - Fort Myers
- Century Clinical Research - Holly Hill
- Ocala Rheumatology Research Center - Ocala
- The Arthritis Center - Palm Harbor
- Radiant Research - Pinellas Park
- Park Place Therapeutic Center - Plantation
Arizona
- Phoenix Center for Clinical Research - Phoenix
- Arizona Research - Phoenix
Georgia
- Comprehensive Neurology Specialists - Atlanta
- Comprehensive Neuroscience - Atlanta
Missouri
- Research Medical Center - Kansas City
- Radiant Research - St Louis
Alabama
- Southern Drug Research - Hueytown
Colorado
- Express Care Clinical Research - Colorado Springs
Delaware
- Glasgow Family Practice - Newark
Illinois
- Pain Specialists of Greater Chicago - Burr Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00226421 record still lists
NCT00226421 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which Oxymorphone Extended Release is the first listed.
NCT00226421 names 20 study sites across 10 states, led by Florida, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT00226421 about?
NCT00226421 is a clinical study titled "Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain". The purpose of this study is to evaluate the analgesic efficacy and safety of oxymorphone extended release in opioid-experienced patients with chronic low back pain.
What is the current status of trial NCT00226421?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2004-10. Estimated completion is 2005-08.
What conditions does trial NCT00226421 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT00226421?
The interventions under investigation include: Oxymorphone Extended Release (DRUG).
Who is sponsoring clinical trial NCT00226421?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00226421 being conducted?
This trial has 20 study locations across Alabama, Arizona, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00226421's enrollment target sits among peer trials
120 120th of 301 higher than 179 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
RECRUITING · Phase 3
-
CARES-Spine (Comprehensive Analgesic, Recovery, and Education Support for Spine Surgery) Trial
RECRUITING · Phase 3
-
Nonpharmacologic Pain Management in FQHC Primary Care Clinics
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Digital Therapeutic for Chronic Pain Feasibility Study
COMPLETED · Phase 3
-
An Implantable Spinal Cord Stimulation Pain Management System
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia